BRIEF-Korro Receives Australian HREC Approval and CTN Clearance

Reuters11-21

Nov 21 (Reuters) - Korro Bio Inc KRRO.O:

KORRO RECEIVES AUSTRALIAN HREC APPROVAL AND CTN CLEARANCE TO INITIATE PHASE 1/2A CLINICAL STUDY (REWRITE) OF KRRO-110 FOR ALPHA-1 ANTITRYPSIN DEFICIENCY
KORRO BIO INC - FIRST PARTICIPANT DOSING EXPECTED IN Q1 2025
KORRO BIO INC - INTERIM READOUT EXPECTED IN H2 2025, STUDY COMPLETION IN 2026

Source text: ID:nGNX7bJg5F

Further company coverage: KRRO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485549887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485549887","market":"us","top_or_hot":-1,"title":"BRIEF-Korro Receives Australian HREC Approval and CTN Clearance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Korro Receives Australian HREC Approval and CTN Clearance</title></head><body><p><span>Nov 21 (Reuters)</span><span> - </span>Korro Bio Inc <span>KRRO.O</span>:</p><ul><li><p>KORRO RECEIVES AUSTRALIAN HREC APPROVAL AND CTN CLEARANCE TO INITIATE PHASE 1/2A CLINICAL STUDY (REWRITE) OF KRRO-110 FOR ALPHA-1 ANTITRYPSIN DEFICIENCY</p></li><li><p>KORRO BIO INC - FIRST PARTICIPANT DOSING EXPECTED IN Q1 2025</p></li><li><p>KORRO BIO INC - INTERIM READOUT EXPECTED IN H2 2025, STUDY COMPLETION IN 2026</p></li></ul><p>Source text: <span>ID:nGNX7bJg5F</span></p><p>Further company coverage: <span>KRRO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Korro Receives Australian HREC Approval and CTN Clearance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Korro Receives Australian HREC Approval and CTN Clearance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 20:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA7XZGB7:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Korro Receives Australian HREC Approval and CTN ClearanceNov 21 (Reuters) - Korro Bio Inc KRRO.O:KORRO RECEIVES AUSTRALIAN HREC APPROVAL AND CTN CLEARANCE TO INITIATE PHASE 1/2A CLINICAL STUDY (...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA7XZGB7:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRRO","symbol_name":"Korro Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA7XZGB7:1","article_id":"2485549887","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485549887","pubTimestamp":1732192534,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Korro Receives Australian HREC Approval and CTN ClearanceNov 21 (Reuters) - Korro Bio Inc KRRO.O:KORRO RECEIVES AUSTRALIAN HREC APPROVAL AND CTN CLEARANCE TO INITIATE PHASE 1/2A CLINICAL STUDY (","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRRO":"Korro Bio, Inc.","BK4139":"生物科技"},"translate_title":"简介-Korro获得澳大利亚HREC批准和CTN许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":0.9},"content_text":"BRIEF-Korro Receives Australian HREC Approval and CTN ClearanceNov 21 (Reuters) - Korro Bio Inc KRRO.O:KORRO RECEIVES AUSTRALIAN HREC APPROVAL AND CTN CLEARANCE TO INITIATE PHASE 1/2A CLINICAL STUDY (REWRITE) OF KRRO-110 FOR ALPHA-1 ANTITRYPSIN DEFICIENCYKORRO BIO INC - FIRST PARTICIPANT DOSING EXPECTED IN Q1 2025KORRO BIO INC - INTERIM READOUT EXPECTED IN H2 2025, STUDY COMPLETION IN 2026Source text: ID:nGNX7bJg5FFurther company coverage: KRRO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":2,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485549887"}